All News

Found 703,836 articles

• Dynamic Technology Solutions Introduces Self-Diagnostic Tool that Measures Product End-of-Life (EOL) Risk Exposure

  1/26/2022

  Dynamic Technology Solutions (Dynamic) announced today the introduction of its EOL PrepSM Self-Diagnostic, based on industry best practices, that provides insights into how well a company is managing risks associated with product End-of-Life (EOL).

• Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo

  1/26/2022

  Silence Therapeutics plc today announced the acceptance of a late-breaking clinical abstract on the ongoing SLN360.

• Mednow Awarded 2022 Best Workplace™ - Start-ups

  1/26/2022

  Mednow Awarded 2022 Best Workplace.

• Polydex Pharmaceuticals Announces Collaboration with Termanox Water Treatment Solutions for novel use of Native DextranPatented cooling water treatment reduces the use of harmful chemicals

  1/26/2022

  Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) is pleased to announce that it has entered into an agreement with Termanox Water Treatment Solutions for a novel use of its native dextran product.

• StemCyte Announces Successful Outcome in Phase I Clinical Trial for Treating Acute Cerebral Stroke Using Allogeneic Human Umbilical Cord Blood

  1/26/2022

  Southern California cord blood therapeutics company StemCyte Inc. is announcing successful preliminary results for Phase I of the company's clinical trial for treating acute cerebral stroke using monocytes from allogeneic human umbilical cord blood (hUCB).

• PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

  1/26/2022

  PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

• Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

  1/26/2022

  Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp.

• Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada

  1/26/2022

  Idorsia Ltd and Syneos Health® announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada.

• Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

  1/26/2022

  Panbela Therapeutics, Inc. (Nasdaq: PBLA), today announced the initiation of the company’s global Phase 2 clinical trial of SBP-101 in combination with Gemcitabine and Nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma, which is referred to as the ASPIRE trial.

• Financial reporting for Essity's new business areas

  1/26/2022

  As of January 1, 2022 , Essity's business areas are Health & Medical, Consumer Goods and Professional Hygiene.

• Medidata Expands and Strengthens Decentralized Clinical Trial (DCT) Capabilities Through Groundbreaking Partnership With Circuit Clinical

  1/26/2022

  Medidata, a Dassault Systèmes company, today announced a groundbreaking and exclusive partnership with Circuit Clinical, an Integrated Research Organization (IRO).

• Checkpoint Surgical Enrolls First Patient in Nerve Regeneration Clinical Study

  1/26/2022

  Checkpoint Surgical, Inc., the leader in intraoperative nerve repair stimulation technology, today announced it has enrolled the first patient in its multi-center clinical study of the company's breakthrough nerve regeneration technology.

• Sharps Compliance Reports Fiscal 2022 Second Quarter Results

  1/26/2022

  Second quarter revenue of $18.9 million increased 11% from the prior year and 36% sequentially.

• Labcorp to Offer Risk-Scoring Test for People With Advanced Liver Fibrosis Due to NASH

  1/26/2022

  For the millions of people in the United States living with an advanced form of chronic liver disease, simply understanding the potential for future complications could help stave off severe damage and even a transplant.

• Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates

  1/26/2022

  Third fiscal quarter 2021 total revenues of $54.4 million, including net product revenue of $29.3 million Net product revenue from U.S. sales of ORGOVYX ® of $24.4 million.

• NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge

  1/26/2022

  NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, has received a first safety report from a Southwestern hospital where physicians have administered ZYESAMI® (Aviptadil) to patients with COVID-19 respiratory failure.

• AccurKardia Announces Collaboration with MDF Instruments to Develop ECG Solutions for the Next Generation of Stethoscopes

  1/26/2022

  AccurKardia, Inc., a software company that provides clinical-grade, device agnostic, automated ECG analytics, today announced a collaboration with MDF Instruments, a highly-regarded and longstanding medical supplier, to develop ECG (electrocardiogram) solutions for the next generation of stethoscopes.

• Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction

  1/26/2022

  NeuroSigma, Inc., a bioelectronic medical device company, and Ignis Therapeutics, a life science company focusing on the central nervous system therapies, jointly announced that Ignis Therapeutics has acquired the exclusive license in China of NeuroSigma’s Monarch eTNS System® to treat attention deficit hyperactivity disorder.

• TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer

  1/26/2022

  TYME Technologies, Inc. today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer.

• Preclinical Study Provides Guidance for Optimizing Safety and Efficacy of Endovascular Hepatic Denervation Devices to Treat Diabetes

  1/26/2022

  CBSET Inc., a not-for-profit translational research institute dedicated to biomedical research, education, and advancement of medical technologies, announced today the publication of its seminal preclinical research “Morphometric analysis of the human common hepatic artery (CHA) reveals a rich and accessible target for sympathetic liver denervation” in Scientific Reports.